HOOKIPA: Application OKd to Start Prostate Cancer Studiy

 HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, has received U.S. Food and Drug Administration (FDA) acceptance of its Investigational New Drug (IND) application for HB-300, a novel arenaviral immunotherapy for the treatment of metastatic castration-resistant prostate cancer.

https://www.biospace.com/article/releases/fda-accepts-hookipa-s-investigational-new-drug-application-for-hb-300-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer/